Publication:
Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea

dc.contributor.authorsDinleyici, E. C.; Kara, A.; Dalgic, N.; Kurugol, Z.; Arica, V.; Metin, O.; Temur, E.; Turel, O.; Guven, S.; Yasa, O.; Bulut, S.; Tanir, G.; Yazar, A. S.; Karbuz, A.; Sancar, M.; Erguven, M.; Akca, G.; Eren, M.; Ozen, M.; Vandenplas, Y.
dc.date.accessioned2022-03-12T20:27:00Z
dc.date.accessioned2026-01-10T17:13:01Z
dc.date.available2022-03-12T20:27:00Z
dc.date.issued2015
dc.description.abstractEvidence from the literature has shown that Saccharomyces boulardii provides a clinically significant benefit in the treatment of acute infectious diarrhoea in children. In this multicentre, randomised, prospective, controlled, single blind clinical trial performed in children with acute watery diarrhoea, we aimed to evaluate the impact of S. boulardii CNCM I-745 in hospitalised children, in children requiring emergency care unit (ECU) stay and in outpatient settings. The primary endpoint was the duration of diarrhoea (in hours). Secondary outcome measures were duration of hospitalisation and diarrhoea at the 3rd day of intervention. In the whole study group (363 children), the duration of diarrhoea was approximately 24 h shorter in the S. boulardii group (75.4 +/- 33.1 vs 99.8 +/- 32.5 h, P<0.001). The effect of S. boulardii (diarrhoea-free children) was observed starting at 48 h. After 72 h, only 27.3% of the children receiving probiotic still had watery diarrhoea, in contrast to 48.5% in the control group (P<0.001). The duration of diarrhoea was significantly reduced in the probiotic group in hospital, ECU and outpatient settings (P<0.001, P<0.01 and P<0.001, respectively). The percentage of diarrhoea-free children was significantly larger after 48 and 72 h in all settings. The mean length of hospital stay was shorter with more than 36 h difference in the S. boulardii group (4.60 +/- 1.72 vs 6.12 +/- 1.71 days, P<0.001). The mean length of ECU stay was shorter with more than 19 h difference in the probiotic group (1.20 +/- 0.4 vs 2.0 +/- 0.3 days, P<0.001). No adverse effects related to the probiotic were noted. Because treatment can shorten the duration of diarrhoea and reduce the length of ECU and hospital stay, there is likely a social and economic benefit of S. boulardii CNCM I-745 in adjunction to oral rehydration solution in acute infectious gastroenteritis in children.
dc.identifier.doi10.3920/BM2014.0086
dc.identifier.eissn1876-2891
dc.identifier.issn1876-2883
dc.identifier.pubmed25653151
dc.identifier.urihttps://hdl.handle.net/11424/233603
dc.identifier.wosWOS:000367160600003
dc.language.isoeng
dc.publisherWAGENINGEN ACADEMIC PUBLISHERS
dc.relation.ispartofBENEFICIAL MICROBES
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSaccharomyces boulardii CNCM I-745
dc.subjectprobiotic
dc.subjectacute diarrhoea
dc.subjectchildren
dc.subjectACUTE GASTROENTERITIS
dc.subjectINFECTIOUS DIARRHEA
dc.subjectPROBIOTICS
dc.subjectGUIDELINES
dc.subjectMANAGEMENT
dc.subjectPREBIOTICS
dc.subjectSAFETY
dc.subjectUPDATE
dc.titleSaccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage421
oaire.citation.issue4
oaire.citation.startPage415
oaire.citation.titleBENEFICIAL MICROBES
oaire.citation.volume6

Files